![]() Struggling to comply with F1 rules, McLaren suffers a series of racing setbacks, and Hunt's situation is further exacerbated when Suzy starts a relationship with actor Richard Burton.įollowing his divorce, Hunt regains his competitive spirit and, when his disqualification in Spain is overturned, the restored points put him into championship contention. Hunt wins the Spanish Grand Prix, but is disqualified after a post-race inspection results in a ruling that the width of his car was greater than permitted. The 1976 season starts with Lauda dominating the first two races while Hunt struggles to catch up. During this time, Hunt marries supermodel Suzy Miller, while Lauda develops a relationship with German socialite Marlene Knaus. Hesketh closes down after failing to secure a sponsor, but Hunt joins the McLaren team. Lauda then joins Scuderia Ferrari with Regazzoni and wins his first championship in 1975. Meanwhile, Hesketh Racing, the fledgling racing team Hunt drives for, enters Formula One. Lauda takes a large bank loan from Austria's Raiffeisen Bank to buy his way into the BRM Formula One team, meeting teammate Clay Regazzoni for the first time. ![]() James Hunt, a brash and self-confident individual, and Niki Lauda, a cool and calculating technical genius who relies on practice and precision, are exceptional racing car drivers who first develop a fierce rivalry in 1970 at a Formula Three race in London, when both their cars spin before Hunt wins the race. The film received positive reviews from critics for Hemsworth and Brühl's performances, Howard's direction, the racing sequences, and Hans Zimmer's musical score. The film premiered in London on 2 September 2013 and was shown at the 2013 Toronto International Film Festival before its United Kingdom release on 13 September 2013. It was written by Peter Morgan, directed by Ron Howard and starred Chris Hemsworth as Hunt and Daniel Brühl as Lauda. Animal studies will not be accepted in this topic.Rush is a 2013 biographical sports film centred on the rivalry between two Formula One drivers, the Briton, James Hunt and the Austrian, Niki Lauda during the 1976 motor-racing season. (3) Clinical parameters related to AIT efficacy: original articles and reviews focus on the clinical parameters and biomarkers related to AIT outcomes are expected. (2) New routes of AIT: pilot studies and randomized controlled trials are expected, fundamental studies related to human are also expected. Original articles and reviews are expected, including randomized controlled trials and real-world studies, both in adults and children. The scope of this Research Topic includes: (1) The efficacy and safety of different treatment regimen of AIT. Integrated indicators involved above clinical parameters and possible biomarkers will be investigated to distinguish AIT responders and non-responders. The minimum clinical important differences (MCID) of these parameters are also to be investigated and validated. The second goal is to validate clinical parameters as indicators of AIT outcome, which included symptom-related parameters, disease control questionnaires and quality of life questionnaires. AIT combined biologicals treatment (such as anti-IgE, anti-IL-4/5/13) are also expected. New routes of AIT are also included, for example, intralymphatic IT, epidermatic IT and rectum route administration. ![]() The first goal of this Research Topic is to evaluate the efficacy and safety profile of different treatment regimens (cluster, rush, adjuvants) which could accelerate the updosing period or reduce treatment frequency of AIT. Easier and simplified clinical indicators are needed in practice. It's also a big challenge for the patients to record their daily symptoms and medication use according to current guidelines in 3-5 years. Meanwhile, there is no reliable biomarkers to predict and evaluate the efficacy of AIT, physicians rely highly on the symptoms and medications scores reported by patients themselves to evaluate if AIT is successful, which is always influenced by recall bias and other factors. ![]() However, AIT is not widely applied currently mainly due to the long term (at lease 3 years) and frequent treatment. The efficacy of AIT has been proved in numerous well-designed randomized controlled trials and real-world studies. Allergen immunotherapy (AIT) is the only disease-modifying treatment for IgE-mediated allergic diseases.
0 Comments
Leave a Reply. |